Journal
IMMUNOTHERAPY
Volume 4, Issue 5, Pages 529-547Publisher
FUTURE MEDICINE LTD
DOI: 10.2217/IMT.12.41
Keywords
experimental autoimmune encephalomyelitis; IFN-gamma; immunomodulation; inflammation; mesenchymal stromal cell; multiple sclerosis; Th17 cell; Toll-like receptor; transplantation
Categories
Funding
- National Center for Regenerative Medicine at Case Western Reserve University
- NIH/NIAID [AI57801, AI089556]
- DOD PRMRP [W81XWH-10-1-0271]
- NIH/NINDS [NS074787]
Ask authors/readers for more resources
Multiple sclerosis (MS) is an inflammatory neurodegenerative disease of the CNS for which only partially effective therapies exist. Intense research defining the underlying immune pathophysiology is advancing both the understanding of MS as well as revealing potential targets for disease intervention. Mesenchymal stromal cell (MSC) therapy has the potential to modulate aberrant immune responses causing demyelination and axonal injury associated with MS, as well as to repair and restore damaged CNS tissue and cells. This article reviews the pathophysiology underlying MS, as well as providing a cutting-edge perspective into the field of MSC therapy based upon the experience of authors intrinsically involved in MS and MSC basic and translational science research.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available